Clinical Trial Update: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients [Phase 2]

View source ↗

Summary

A Phase 2 two-week dosing trial of LCQ908 in Hepatitis C patients assessing safety and antiviral activity; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• LCQ908

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatitis C | Phase 2 | Status: TERMINATED